Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Hatim Sabaawy

TitleProfessor
InstitutionUniversity of Colorado Denver - Anschutz Medical Campus
DepartmentSOM-MED

    Collapse Biography 
    Collapse education and training
    New York Medical College, Valhalla, NYMD, PhD05/2002Medicine/Gene Therapy
    National Cancer Institute, Bethesda, MDFellow08/2007Transplantation & Immunology
    Rutgers Leadership Academy, Piscataway, NJRLA Certification04/2021Leadership, Academic Medicine
    Collapse awards and honors
    1999Current Awareness in Biomedicine, Gene Therapy Institute
    2001Excellence in Research Award, National Student Forum
    2004 - 2006Cancer Research Training Award, NIH
    2006Award of Merit, NIH
    2010Stem cell Global Blueprint Award, University of Toronto
    2015Breakthrough Session Award, Prostate Cancer Foundation
    2017 - 2019Patent Award, Rutgers University Office of Research Commercialization
    2018Clinical Investigator Nomination, American Society of Clinical Investigators (ASCI)
    2020 - 2021Personalized Medicine Capstone Project, Rutgers Leadership Academy

    Collapse Overview 
    Collapse overview
    A translation-focused investigator specializing in developmental therapeutics, correlative science, and precision medicine, with 15+ years of continuous NIH and federal funding. Research is focused on identifying novel therapeutic paradigms to enhance self-renewal, in stem cells and organoids for regeneration, and inhibit tumor self-renewal, in cancer stem-like cells (CSCs), for targeting cancer cell plasticity. Our team utilizes genetic reporters to develop first-in-class inhibitors to target CSCs and discover novel immune modulatory activities using organoids, PDXs or genetically engineered mouse models (GEMMs), guided by spacial profiling and single cell-derived organoids. The novel patient derived organoid (PDO) technology has been recently licensed to make it easier for many laboratories to utilize it for developing predictive biomarkers, optimized readouts for drug responses, and effective medical paradigms with personalized medicine.
    I work with my colleagues at the Cancer Center leadership team to serve as Associate Director for Translational Research, and Director of Personalized Medicine at the Division Medical Oncology. My role is to ensure that translational research relevant to Colorado cancer patients is conducted and facilitate the translation of laboratory findings, including agents, technologies, and treatment strategies, into investigator-initiated trials (IITs), with emphasis on personalized and combined therapy. I am deeply committed to translating basic research to the clinic, translating clinical findings back to basic research, and reducing disparities in cancer outcomes in low-income and under-represented minority patients and patients from rural CO.
    In a key initiative, I am leading a new precision medicine program for systematic use of tissue biopsies for generation of 1) precision diagnostics (Dx) (with single cell and spacial multiomic assays) to provide unparalleled depth and richness of spatially-intact, scientific- and clinical-grade, single cell signatures from tumor biopsies, and 2) precision therapeutics (Tx) with PDO drug testing and high throughput screening, that promise to offer life-saving treatments and fuel new discoveries for health, diseases, and data science.
    Collapse keywords

    Collapse Research 
    Collapse research activities and funding
    AWD-232449     (SABAAWY, HATIM)Sep 1, 2023 - Jun 30, 2024
    Cancer League of Colorado
    Targeting the BMI1 oncogene mRNA using small molecules
    Role Description: The goal is to study the mechanism of targeting oncogenic RNA.
    Role: Principal Investigator

    7R01CA226746     (SABAAWY, HATIM)Jul 2, 2023 - Jun 30, 2024
    NIH/NCI
    Mechanisms of targeting cellular self-renewal in glioblastoma
    Role Description: This award is continue the development of BMI1-targeted therapy using glioblastoma organoids and mouse models.
    Role: Principal Investigator

    R01CA256893     (LIU, XIAOQI)Jul 1, 2021 - Jun 30, 2026
    NIH
    Enhancing the efficacy of androgen signaling inhibitors in prostate cancer
    Role: Co-Investigator

    R01CA239093     (PINE, SHARON R.)May 15, 2020 - Apr 30, 2025
    NIH
    Discovery and therapeutic targeting of biological determinants of lung cancer health disparities
    Role: Co-Investigator

    CSR19IRG0014     (SABAAWY, HATIM)Dec 1, 2018 - Nov 30, 2021
    New Jersey Commission on Spinal Cord Research
    Mechanisms of regeneration and neural repair
    Role Description: This award is to study endogenous lineage contribution to neural repair in mouse models.

    R01CA226746     (SABAAWY, HATIM)Jul 2, 2018 - Jun 30, 2023
    NIH
    Mechanisms of targeting cellular self-renewal in glioblastoma
    Role: Principal Investigator

    HHS-S18-054     (SABAAWY, HATIM)May 1, 2018 - Apr 30, 2019
    NIH/Leidos
    4D printing of programmable smart material for processing of cellular spheres and organoids
    Role Description: The goal was to develop transforming material with 3D printing of human patient derived organoid models of brain tumors.
    Role: Principal Investigator

    CSR16IRG005     (SABAAWY, HATIM)Jul 1, 2017 - Jun 30, 2020
    New Jersey Commission on Spinal Cord Research
    Mechanisms underlying bone marrow transplant driven activation of endogenous stem cells for spinal cord injury repair
    Role Description: The goal is to study the mechanism of cell repair with Rutgers technologies for bone-marrow derived cell therapy.
    Role: Principal Investigator

    F31DC016239     (LAUREANO RUIZ, ALEJANDRA SOFIA)Jan 9, 2017 - Jan 8, 2020
    NIH
    Role of shox2 in zebrafish otic neuron development
    Role: Co-Investigator

    R21HD083616     (COPELAND, PAUL R)Apr 1, 2016 - Mar 31, 2020
    NIH
    Development of a zebrafish model for selenoprotein synthesis and function
    Role: Co-Investigator

    NA     (SABAAWY, HATIM)Jan 1, 2016 - Dec 31, 2016
    New Jersey Health Foundation
    Bioengineering of organoids from lung and breast cancer and glioblastoma
    Role: Principal Investigator

    R01CA190578     (PINE, SHARON R.)Sep 19, 2014 - Aug 31, 2021
    NIH
    Sox9 signaling in lung adenocarcinoma
    Role: Co-Investigator

    W81XWH-12-1-0249     (SABAAWY, HATIM)Oct 1, 2012 - Sep 30, 2016
    Department of Defense
    Therapeutic role of inhibitors eliminating prostate tumor stem cells
    Role Description: This synergy program project included three PIs with projects focused on developing novel prostate cancer therapy.
    Role: Contact Principal Investigator

    09-1137-CCR-EO     (SABAAWY, HATIM)Jul 1, 2010 - Apr 30, 2012
    New Jersey Commission on Cancer Research
    The IMPACT of prostate cancer stem cell therapy
    Role Description: The goal of this project was to develop targeted therapy against cancer stem cells in prostate tumors.
    Role: Principal Investigator

    NA     (SABAAWY, HATIM)Sep 1, 2009 - Aug 30, 2010
    Leukemia Research Foundation
    The role of ETV6/TEL in lymphoid neoplasia
    Role Description: The goal was to study the prevailance of ETV6 mutations in lymphoma.
    Role: Principal Investigator

    K22CA120626     (SABAAWY, HATEM)Sep 19, 2007 - Aug 31, 2010
    NIH
    TEL-AML1 Transgenic Zebrafish Model of Human Leukemia
    Role: Principal Investigator

    K12CA086913     (BORGES, VIRGINIA F. ;SLANSKY, JILL E)Sep 18, 2000 - Aug 31, 2024
    NIH
    Paul Calabresi Award in Clinical Oncology Research
    Role: Co-Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Liu L, Strange A, Lee S, Gao B, Merrick D, Patil T, DeGregori J, Camidge DR, Pine, SR, SabaawyHE. Assessment of tyrosine kinase inhibitor bypass mechanisms in lung cancer using single cell multiomics, patient derived organoids and rationally designed drug screens. 2024; 24-A-5910-AACR.
    2. Sabaawy, H. US 11,834,680. Single kidney cell-derived organoids. 2023.
    3. Sabaawy, H. Precision Oncology Keynote. 25th International Charles Heidelberger Symposium on Cancer Research. 2023.
    4. Zhong H, Lu W, Tang Y, Wiel C, Wei Y, Cao J, Riedlinger G, Papagiannakopoulos T, Guo JY, Bergo MO, Kang Y, Ganesan S, Sabaawy HE, Pine SR. SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity. Oncogene. 2023 Jun; 42(27):2183-2194. PMID: 37258742.
      View in: PubMed
    5. Pine S; Zhong, and Sabaawy HE. RNAseq data on control (TC11EV1-4) and Sox9 overexpressing (TC11S1-4) murine lung adenocarcinoma syngeneic allograft samples. 2023; https://doi.org/10.6084/m9.fig.
    6. Sabaawy HE, Broggini M, Gupta SK. Patient-derived tumor models for drug development. Front Oncol. 2023; (13):1243534.
    7. Laureano AS, Flaherty K, Hinman AM, Jadali A, Nakamura T, Higashijima SI, Sabaawy HE, Kwan KY. shox2 is required for vestibular statoacoustic neuron development. Biol Open. 2022 12 15; 11(12). PMID: 36594417.
      View in: PubMed
    8. Castellano GM, Zeeshan S, Garbuzenko OB, Sabaawy HE, Malhotra J, Minko T, Pine SR. Inhibition of Mtorc1/2 and DNA-PK via CC-115 Synergizes with Carboplatin and Paclitaxel in Lung Squamous Cell Carcinoma. Mol Cancer Ther. 2022 09 06; 21(9):1381-1392. PMID: 35732569.
      View in: PubMed
    9. Kim IY, Mitrofanova A, Panja S, Sterling J, Srivastava A, Kim J, Kim S, Singer EA, Jang TL, Ghodoussipour S, Saraiya B, Mayer T, Sabaawy HE, Yuh B, Byun SS, Kim WJ, Horie S. Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. Prostate Int. 2022 Jun; 10(2):75-79. PMID: 35510081.
      View in: PubMed
    10. Sabaawy HE, Ryan BM, Khiabanian H, Pine SR. JAK/STAT of all trades: linking inflammation with cancer development, tumor progression and therapy resistance. Carcinogenesis. 2021 12 31; 42(12):1411-1419. PMID: 34415330.
      View in: PubMed
    11. Gamboa CM, Wang Y, Xu H, Kalemba K, Wondisford FE, Sabaawy HE. Optimized 3D Culture of Hepatic Cells for Liver Organoid Metabolic Assays. Cells. 2021 11 24; 10(12). PMID: 34943788.
      View in: PubMed
    12. Sabaawy, H, Bartucci, M. Single cell derived organoids. 2021.
    13. Pamarthy S, Sabaawy HE. Patient derived organoids in prostate cancer: improving therapeutic efficacy in precision medicine. Mol Cancer. 2021 09 29; 20(1):125. PMID: 34587953.
      View in: PubMed
    14. Sabaawy, H. BIG TEN cancer research consortium clinical trial working group. Correlative studies in clinical trials. 2021.
    15. Gamboa CM, Jara K, Pamarthy S, Liu L, Aiken R, Xiong Z, Danish S, Sabaawy HE. Generation of glioblastoma patient-derived organoids and mouse brain orthotopic xenografts for drug screening. STAR Protoc. 2021 03 19; 2(1):100345. PMID: 33665625.
      View in: PubMed
    16. Al-Zubaydi F, Gao D, Kakkar D, Li S, Holloway J, Szekely Z, Chan N, Kumar S, Sabaawy HE, Love S, Sinko PJ. Breast intraductal nanoformulations for treating ductal carcinoma in situ II: Dose de-escalation using a slow releasing/slow bioconverting prodrug strategy. Drug Deliv Transl Res. 2022 01; 12(1):240-256. PMID: 33590464.
      View in: PubMed
    17. Augeri, DJ, Sabaawy, H. Therapeutic compounds. 2020.
    18. Lee GT, Nagaya N, Desantis J, Madura K, Sabaawy HE, Kim WJ, Vaz RJ, Cruciani G, Kim IY. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy. Mol Cancer Ther. 2021 03; 20(3):490-499. PMID: 33277442.
      View in: PubMed
    19. Yang C, Luo J, Polunas M, Bosnjak N, Chueng SD, Chadwick M, Sabaawy HE, Chester SA, Lee KB, Lee H. 4D-Printed Transformable Tube Array for High-Throughput 3D Cell Culture and Histology. Adv Mater. 2020 Oct; 32(40):e2004285. PMID: 32864842.
      View in: PubMed
    20. Chadwick M, Yang C, Liu L, Gamboa CM, Jara K, Lee H, Sabaawy HE. Rapid Processing and Drug Evaluation in Glioblastoma Patient-Derived Organoid Models with 4D Bioprinted Arrays. iScience. 2020 Aug 21; 23(8):101365. PMID: 32731171.
      View in: PubMed
    21. Yang C. Chadwick M, Sabaawy H, Lee H. The Society of Engineering Science (SES). 4D printed transformable cell-culture insert for a standard well plate for rapid target validation and drug evaluation in patient derived organoids. 2019.
    22. Chadwick M, Mfon R, Jara K, Danish S, Aiken R, and Sabaawy H. . In: Proceedings of the 110th Annual Meeting of the American Association for Cancer Research; 2019 Mar 30-Apr 2; Atlanta, GA Philadelphia (PA): AACR. Single cell derived 3D organoids recapitulate the tumorigenic features of glioblastoma. 2019.
    23. Chadwick M, Huselid E, Bartucci M, Patrizii M, Jara K, Mehta M, Gilleran J, Augeri, and Sabaawy, H. Development of novel BMI1 inhibitors targeting glioblastoma stem-like cells. 2019.
    24. Sabaawy, H. Nature Reviews Urology. Prostate cancer patient derived organoids (PDOs). 2019.
    25. Pine SR, Sabaawy HE. Editorial: Harnessing the Power of Patient Derived Models of Cancer. Front Oncol. 2018; 8:349. PMID: 30237982.
      View in: PubMed
    26. Sabaawy, H. American Association of Blood Banking. Harnessing the Power of Cellular Products for Regeneration and Immunotherapy. 2018.
    27. Patrizii M, Bartucci M, Pine SR, Sabaawy HE. Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol. 2018; 8:23. PMID: 29484285.
      View in: PubMed
    28. Bartucci M, Hussein MS, Huselid E, Flaherty K, Patrizii M, Laddha SV, Kui C, Bigos RA, Gilleran JA, El Ansary MMS, Awad MAM, Kimball SD, Augeri DJ, Sabaawy HE. Synthesis and Characterization of Novel BMI1 Inhibitors Targeting Cellular Self-Renewal in Hepatocellular Carcinoma. Target Oncol. 2017 08; 12(4):449-462. PMID: 28589491.
      View in: PubMed
    29. Ferrari AC, Sabaawy H, Stein M, Foran D, Chen Y, Yegnasubramanian S. Genome-wide alterations in gene expression of prostate cancer (PC) cells surviving neo-adjuvant androgen deprivation therapy. . 2017.
    30. Hong X, Liu W, Song R, Shah JJ, Feng X, Tsang CK, Morgan KM, Bunting SF, Inuzuka H, Zheng XF, Shen Z, Sabaawy HE, Liu L, Pine SR. SOX9 is targeted for proteasomal degradation by the E3 ligase FBW7 in response to DNA damage. Nucleic Acids Res. 2016 Oct 14; 44(18):8855-8869. PMID: 27566146.
      View in: PubMed
    31. Bartucci M, Ferrari AC, Kim IY, Ploss A, Yarmush M, Sabaawy HE. Personalized Medicine Approaches in Prostate Cancer Employing Patient Derived 3D Organoids and Humanized Mice. Front Cell Dev Biol. 2016; 4:64. PMID: 27446916.
      View in: PubMed
    32. Bansal N, Bartucci M, Yusuff S, Davis S, Flaherty K, Huselid E, Patrizii M, Jones D, Cao L, Sydorenko N, Moon YC, Zhong H, Medina DJ, Kerrigan J, Stein MN, Kim IY, Davis TW, DiPaola RS, Bertino JR, Sabaawy HE. BMI-1 Targeting Interferes with Patient-Derived Tumor-Initiating Cell Survival and Tumor Growth in Prostate Cancer. Clin Cancer Res. 2016 Dec 15; 22(24):6176-6191. PMID: 27307599.
      View in: PubMed
    33. Samir A, Elgamal BM, Gabr H, Sabaawy HE. Nanotechnology applications in hematological malignancies?(Review). Oncol Rep. 2015 Sep; 34(3):1097-105. PMID: 26134389.
      View in: PubMed
    34. Misra K, Sabaawy HE. Minimally manipulated autologous adherent bone marrow cells (ABMCs): a promising cell therapy of spinal cord injury. Neural Regen Res. 2015 Jul; 10(7):1058-60. PMID: 26330823.
      View in: PubMed
    35. Tiku ML, Sabaawy HE. Cartilage regeneration for treatment of osteoarthritis: a paradigm for nonsurgical intervention. Ther Adv Musculoskelet Dis. 2015 Jun; 7(3):76-87. PMID: 26029269.
      View in: PubMed
    36. Mehta M, Khan A, Danish S, Haffty BG, Sabaawy HE. Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition. Mol Cancer Ther. 2015 May; 14(5):1171-80. PMID: 25695954.
      View in: PubMed
    37. Bertino J, Sabaawy HE, Kim I. dtic.mil. Therapeutic Role of Bmi-1 Inhibitors in Eliminating Prostate Tumor Stem Cells. 2015; ADA612054.
    38. Granier CJ, Wang W, Tsang T, Steward R, Sabaawy HE, Bhaumik M, Rabson AB. Conditional inactivation of PDCD2 induces p53 activation and cell cycle arrest. Biol Open. 2014 Aug 22; 3(9):821-31. PMID: 25150276.
      View in: PubMed
    39. Gabr H, El-Kheir WA, Farghali HA, Ismail ZM, Zickri MB, El Maadawi ZM, Kishk NA, Sabaawy HE. Intrathecal Transplantation of Autologous Adherent Bone Marrow Cells Induces Functional Neurological Recovery in a Canine Model of Spinal Cord Injury. Cell Transplant. 2015; 24(9):1813-27. PMID: 25199146.
      View in: PubMed
    40. Sabaawy HE. Genetic Heterogeneity and Clonal Evolution of Tumor Cells and their Impact on Precision Cancer Medicine. J Leuk (Los Angel). 2013 Nov 18; 1(4):1000124. PMID: 24558642.
      View in: PubMed
    41. Bansal N, Davis S, Tereshchenko I, Budak-Alpdogan T, Zhong H, Stein MN, Kim IY, Dipaola RS, Bertino JR, Sabaawy HE. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. Prostate. 2014 Feb; 74(2):187-200. PMID: 24154958.
      View in: PubMed
    42. Balow SA, Pierce LX, Zentner GE, Conrad PA, Davis S, Sabaawy HE, McDermott BM, Scacheri PC. Knockdown of fbxl10/kdm2bb rescues chd7 morphant phenotype in a zebrafish model of CHARGE syndrome. Dev Biol. 2013 Oct 01; 382(1):57-69. PMID: 23920116.
      View in: PubMed
    43. El-Kheir WA, Gabr H, Awad MR, Ghannam O, Barakat Y, Farghali HA, El Maadawi ZM, Ewes I, Sabaawy HE. Autologous bone marrow-derived cell therapy combined with physical therapy induces functional improvement in chronic spinal cord injury patients. Cell Transplant. 2014 Apr; 23(6):729-45. PMID: 23452836.
      View in: PubMed
    44. Kokorina NA, Granier CJ, Zakharkin SO, Davis S, Rabson AB, Sabaawy HE. PDCD2 knockdown inhibits erythroid but not megakaryocytic lineage differentiation of human hematopoietic stem/progenitor cells. Exp Hematol. 2012 Dec; 40(12):1028-1042.e3. PMID: 22922207.
      View in: PubMed
    45. Kramer J, Granier CJ, Davis S, Piso K, Hand J, Rabson AB, Sabaawy HE. PDCD2 controls hematopoietic stem cell differentiation during development. Stem Cells Dev. 2013 Jan 01; 22(1):58-72. PMID: 22800338.
      View in: PubMed
    46. El Ansary M, Mogawer S, Elhamid SA, Alwakil S, Aboelkasem F, Sabaawy HE, Abdelhalim O. Immunotherapy by autologous dendritic cell vaccine in patients with advanced HCC. J Cancer Res Clin Oncol. 2013 Jan; 139(1):39-48. PMID: 22886490.
      View in: PubMed
    47. Patel N, Klassert TE, Greco SJ, Patel SA, Munoz JL, Reddy BY, Bryan M, Campbell N, Kokorina N, Sabaawy HE, Rameshwar P. Developmental regulation of TAC1 in peptidergic-induced human mesenchymal stem cells: implication for spinal cord injury in zebrafish. Stem Cells Dev. 2012 Jan 20; 21(2):308-20. PMID: 21671725.
      View in: PubMed
    48. Yu YM, Gibbs KM, Davila J, Campbell N, Sung S, Todorova TI, Otsuka S, Sabaawy HE, Hart RP, Schachner M. MicroRNA miR-133b is essential for functional recovery after spinal cord injury in adult zebrafish. Eur J Neurosci. 2011 May; 33(9):1587-97. PMID: 21447094.
      View in: PubMed
    49. Miles G, Rajagopal G, Strair R, and Sabaawy HE. Identification and modeling of TEL-AML1 (ETV6-RUNX1) molecular signature in acute lymphoblastic leukemia. Blood. 2010; 21(116):2500.
    50. Bansal N, Campbell N, Medina D, Kramer J, Bertino JR, and Sabaawy HE. Targeting Bmi1 in human prostate tumor initiating cells. Cancer Research. 2009; 8(70):4279.
    51. Kramer JJ, Minakhina S, Campbell N, Marshall S, Piso K, Rabson AB, and Sabaawy HE. Alternative splicing of PDCD2 regulates hematopoietic stem cell specification and drives multilineage leukemia development. Blood. 2009; 22(114):258.
    52. Azuma M, Embree LJ, Sabaawy H, Hickstein DD. Ewing sarcoma protein ewsr1 maintains mitotic integrity and proneural cell survival in the zebrafish embryo. PLoS One. 2007 Oct 03; 2(10):e979. PMID: 17912356.
      View in: PubMed
    53. Sabaawy HE, Sandoval C, Guo Q, Yin C, Kulangara A, Lee J, Wormser G, Jayabose S, Pine SR. Lymphoproliferative clonal origin of AIDS-related non-Hodgkin's lymphoma. Leuk Lymphoma. 2007 Apr; 48(4):812-5. PMID: 17454643.
      View in: PubMed
    54. Sabaawy HE, Azuma M, Embree LJ, Tsai HJ, Starost MF, Hickstein DD. TEL-AML1 transgenic zebrafish model of precursor B cell acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2006 Oct 10; 103(41):15166-71. PMID: 17015828.
      View in: PubMed
    55. Pine SR, Yin C, Matloub YH, Sabaawy HE, Sandoval C, Levendoglu-Tugal O, Ozkaynak MF, Jayabose S. Detection of central nervous system leukemia in children with acute lymphoblastic leukemia by real-time polymerase chain reaction. J Mol Diagn. 2005 Feb; 7(1):127-32. PMID: 15681484.
      View in: PubMed
    56. Sacerdoti D, McGiff J, Oyeken A, Yang L, Sabaawy HE, A. Gatta A. and NG Abraham. Transfection of rat cells with human Heme-Oxygenase-1 gene reproduces abnormalities of the mesenteric circulation of cirrhosis. Journal of Hepatology. 2002; (34):13.
    57. Sabaawy HE, Zhang F, Nguyen X, ElHosseiny A, Nasjletti A, Schwartzman M, Dennery P, Kappas A, Abraham NG. Human heme oxygenase-1 gene transfer lowers blood pressure and promotes growth in spontaneously hypertensive rats. Hypertension. 2001 Aug; 38(2):210-5. PMID: 11509478.
      View in: PubMed
    58. da Silva JL, Zand BA, Yang LM, Sabaawy HE, Lianos E, Abraham NG. Heme oxygenase isoform-specific expression and distribution in the rat kidney. Kidney Int. 2001 Apr; 59(4):1448-57. PMID: 11260407.
      View in: PubMed
    59. Sabaawy HE and Abraham NG. Functional expression of human heme oxygenase-1 in vivo using retroviral vector. Journal of Investigative Medicine. 2000; 2(48):201A.
    60. Sabaawy HM, Ikehara S, Adachi Y, Quan S, Feldman E, Kancherla R, Abraham NG, Ahmed T. Enhancement of 5-fluorouracil cytotoxicity on human colon cancer cells by retrovirus-mediated interferon-alpha gene transfer. Int J Oncol. 1999 Jun; 14(6):1143-51. PMID: 10339671.
      View in: PubMed
    61. Sabaawy HE, Farley T, Ahmed T, Feldman E, Abraham NG. Synergetic effects of retrovirus IFN-alpha gene transfer and 5-FU on apoptosis of colon cancer cells. Acta Haematol. 1999; 101(2):82-8. PMID: 10202238.
      View in: PubMed
    Sabaawy's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)